Breaking News Instant updates and real-time market news.

P

Pandora

$8.23

-0.09 (-1.08%)

, AAPL

Apple

$156.07

-2.66 (-1.68%)

06:31
09/21/17
09/21
06:31
09/21/17
06:31

Music subscriptions accelerate in first half of 2017, WSJ reports

In the U.S., revenue from recorded music grew 17% in the first half of 2017 as more consumers paid for subscription streaming services, The Wall Street Journal reports. Reference Link

P

Pandora

$8.23

-0.09 (-1.08%)

AAPL

Apple

$156.07

-2.66 (-1.68%)

GOOG

Alphabet

$931.58

9.77 (1.06%)

GOOGL

Alphabet Class A

$947.54

10.68 (1.14%)

  • 22

    Oct

  • 29

    Nov

P Pandora
$8.23

-0.09 (-1.08%)

08/01/17
WEDB
08/01/17
NO CHANGE
WEDB
Pandora to reach profitability faster than previously expected, says Wedbush
After Pandora reported lower than expected revenue but a lower than expected loss, Wedbush analyst Michael Pachter thinks that the company's subscription totals and marketing spending will be lower than he previously expected. As a result;, he expects Pandora to return to profitability more quickly than he previously believed and says that "a return to profitability" this year has become more likely. The analyst keeps a $15 price target and an Outperform rating on the stock.
08/01/17
STFL
08/01/17
NO CHANGE
STFL
Pandora price target lowered to $12 from $14 at Stifel
After Pandora reported a lower than expected Q2 per share loss but lowered its revenue guidance, Stifel analyst John Egbert reduced his price target "to reflect a more modest near-term growth outlook." However, the analyst noted that the company expects trends in its ad business to improve in 2H17, and he says that the company's Premium business grew at a "healthy" rate. He keeps a Buy rating on the stock.
08/01/17
BOFA
08/01/17
NO CHANGE
Target $7.5
BOFA
Underperform
Pandora price target lowered to $7.50, no turnaround in sight, says BofA/Merrill
BofA/Merrill analyst Nat Schindler said Pandora reported a Q1 beat but guidance was well below the Street. The analyst thinks structural problems are deep and said its hard to see how the model will work without major cost cutting. Schindler said Pandora is challenged by declining users and cut his price target to $7.50 from $9 and reiterated its Underperform rating.
08/15/17
STFL
08/15/17
NO CHANGE
STFL
New executives could be 'very valuable' to Pandora, says Stifel
Stifel analyst John Egbert says that Pandora's new CEO, Roger Lynch, and its new board member, Michael Lynton , "bring decades of valuable experience as high-ranking media executives, which Pandora can surely use more of at this junction." The analyst says that the pair's "experience and expertise..could be very valuable to Pandora." The analyst keeps a $12 price target and a Buy rating on the shares.
AAPL Apple
$156.07

-2.66 (-1.68%)

09/19/17
MSCO
09/19/17
NO CHANGE
Target $194
MSCO
Overweight
Apple price target raised to $194 on higher average prices at Morgan Stanley
Morgan Stanley analyst Katy Huberty said its aspirational brand, high loyalty, and the weaker U.S. dollar all contribute to letting Apple increase prices without hurting demand, calling an uplift in average selling prices for iPhones the "key takeaway" from Apple's recent product launch event. The analyst, who noted that innovation-led price increases historically boost, rather than hurt, Apple demand, increased her FY18 EPS estimate for Apple and raised her price target on the stock to $194 from $182. Huberty keeps an Overweight rating on Apple shares.
09/15/17
09/15/17
UPGRADE
Target $62.5

Outperform
Qualcomm upgraded to Outperform on 3D sensing opportunity at Northland
As previously reported, Northland analyst Tom Sepenzis upgraded Qualcomm (QCOM) to Outperform from Market Perform on expectations for market share gains in 2018, particularly at the high end, as he sees the company and partner Himax (HIMX) as well positioned to become the "de facto leading 3D sensing solution" with Android manufacturers who follow the lead of Apple's (AAPL) new iPhone X. From what he understands, handset makers that want to use its SLiM structured light solution will have to use Qualcomm's next generation Snapdragon chipset too, he tells investors. Sepenzis keeps a $62.50 price target on Qualcomm shares.
09/15/17
KEYB
09/15/17
NO CHANGE
Target $62
KEYB
Overweight
Criteo has workaround to Apple cookie disabler, says KeyBanc
KeyBanc analyst Andy Hargreaves recommends buying Criteo (CRTO) after the company at an event yesterday detailed its Commerce Marketing Platform, which aggregates online and offline data across partners to create a "Shopper Graph." The product has the potential to create new product areas, deepen partnerships and expand Criteo's "moat," Hargreaves tells investors in a research note. The stock has been weak on Apple's (AAPL) upcoming Intelligent Tracking Prevention rollout, which attempts to disable third-party tracking cookies after 24 hours, Hargreaves points out. He sees the issue as transitory, however, noting Criteo has a workaround that he believes will prove effective with direct publisher relationships. The analyst views Criteo's risk/reward as attractive and keeps an Overweight rating on the name with a $62 price target.
09/20/17
RSBL
09/20/17
NO CHANGE
RSBL
Apple iPhone 8 preorder volume below prior models, says Rosenblatt
Rosenblatt analyst Jun Zhang said checks indicate about 1.5M iPhone 8 preorders on JD.com (JD) in the first three days, versus 3.5M for the iPhone 7 in the first three days. He also thinks China Mobile's (CHL) iPhone 8 preorder volumes are around 1M units, compared to 2.5M iPhone 7 units and 3.5M iPhone 6 units, for the first three days. For the U.S., Zhang said initial feedback also suggests iPhone 8 preorder volume below the iPhone 7 and iPhone 6. The analyst remains concerned iPhone 8 production plan of approximately 70M units for second half 2017 might need to be cut and the iPhone X production ramp might not be able to meet demand for the December and March quarters.
GOOG Alphabet
$931.58

9.77 (1.06%)

09/18/17
MSCO
09/18/17
NO CHANGE
MSCO
Underweight
Ford's new leaders may be better positioned for Waymo deal, says Morgan Stanley
Morgan Stanley analyst Adam Jonas previewed Ford's (F) strategic update scheduled for October 3, calling it an important event that could have a potentially significant impact on the perception of the company's long-term direction. Noting prior media reports about talks between Ford and Google (GOOG) on autonomous cars that reportedly fell apart in 2016, Jonas opined that Ford's new leadership may be better positioned to potentially negotiate a partnership with Alphabet's autonomous car division Waymo, but he noted that the companies have not said whether they are currently considering a deal. Ford may not have the same type of brands as Fiat Chrysler (FCAU) that are conducive to potential carve-outs, but Jonas would not exclude the potential for it to conduct a review of its portfolio as part of its strategy to become a mobility company, he added.
09/20/17
SBSH
09/20/17
NO CHANGE
Target $1180
SBSH
Buy
Alphabet checks suggest at least in line Q3, says Citi
Citi analyst Mark May says early checks with two leading search engine marketing firms, Merkle and Kenshoo, suggest that growth in Google search spend remains strong and that the company is on track to at least meet expectations in Q3. The analyst keeps a Buy rating on Alphabet (GOOGL) shares with a $1,180 price target.
09/14/17
BARD
09/14/17
NO CHANGE
Target $1100
BARD
Outperform
Alphabet TAC cost may moderate in coming quarters, says Baird
Baird analyst Colin Sebastian said his analysis suggests traffic acquisition cost, or TAC, headwinds for Google may moderate in coming quarters. He believes Alphabet shares have been range bound due to TAC-related margin pressures, but they could moderate earlier than many investors anticipate, in part due to the company lapping distribution agreements. Sebastian reiterated his Outperform rating and $1,100 price target on Alphabet shares.
09/19/17
KEYB
09/19/17
NO CHANGE
KEYB
KeyBanc remains positive on Activision Blizzard, Electronic Arts
KeyBanc analyst Evan Wingren remains positive on Activision Blizzard (ATVI), Electronic Arts (EA), and Take-Two (TTWO) after attending eSCon, a small eSports conference in Los Angeles. The analyst believes interest and momentum in the space remains high, and continues to think the majority of the economics in the industry will accrue to IP owners and scaled technology partners. Therefore, Wingren continues to see the publishers as well-positioned, as well as Amazon's (AMZN) Twitch, Google's (GOOG; GOOGL) YouTube, and Facebook (FB).
GOOGL Alphabet Class A
$947.54

10.68 (1.14%)

09/12/17
MSCO
09/12/17
NO CHANGE
MSCO
Augmented Reality the next 'killer app' to power Apple, says Morgan Stanley
A team of Morgan Stanley analysts including Katy Huberty, Brian Nowak and Grace Chen, among others, state in a new note to investors that they view Augmented Reality, or AR, as a revolutionary trend that can be "the next killer app" to extend the life of the smartphone market and accelerate device upgrades, led by Apple's (AAPL) iPhone. The analysts, who compare the impact of AR to the launch of Apple's App Store nearly a decade ago, add that they "don't expect the Android ecosystem to stand still in response." Huberty and the team raised the firm's "bull case" valuation of Apple, which they see taking the lead in AR, to $253 from $203. While they see Apple as "the clear leader" in AR, Google (GOOG) and Tencent (TCEHY) are also well-positioned and "interesting use cases" in e-commerce could benefit Alibaba (BABA) and Amazon (AMZN), they add.

TODAY'S FREE FLY STORIES

GNRC

Generac

$50.49

-0.4 (-0.79%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Recommendations
Generac analyst commentary  »

Generac estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

ADP

ADP

$113.72

-0.86 (-0.75%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Periodicals
Ackman increases pressure on ADP over tech development, WSJ reports »

Activist investor and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

PRKR

ParkerVision

$1.50

-0.06 (-3.85%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Hot Stocks
ParkerVision enters common stock purchase agreement with Aspire Capital »

ParkerVision announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$9.23

0.15 (1.65%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Technical Analysis
Technical View: GoPro trades higher, analyst action »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NAVI

Navient

$12.20

0.47 (4.01%)

07:17
10/18/17
10/18
07:17
10/18/17
07:17
Hot Stocks
Navient sees adding over $1B of education refinance loans in FY17 »

Including the planned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Conference/Events
Commodity Futures Trading Commission Commissioners to speak at Expo »

Brian Quintenz and Rostin…

FGEN

FibroGen

$55.30

0.8 (1.47%)

, AZN

AstraZeneca

$34.78

0.13 (0.38%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Hot Stocks
FibroGen announces CFDA acceptance of roxadustat NDA »

FibroGen (FGEN) and its…

FGEN

FibroGen

$55.30

0.8 (1.47%)

AZN

AstraZeneca

$34.78

0.13 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 08

    Nov

  • 09

    Nov

CMG

Chipotle

$329.30

8.91 (2.78%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Technical Analysis
Technical View: Chipotle falls, analyst actions »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

UNH

UnitedHealth

$203.89

10.69 (5.53%)

, AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Recommendations
UnitedHealth, Amazon.com analyst commentary  »

UnitedHealth price target…

UNH

UnitedHealth

$203.89

10.69 (5.53%)

AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 18

    Mar

AAN

Aaron's

$41.55

0.01 (0.02%)

07:15
10/18/17
10/18
07:15
10/18/17
07:15
Initiation
Aaron's initiated  »

Aaron's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

, FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Conference/Events
FDIC to hold a committee meeting »

The FDIC's Advisory…

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

ONB

Old National Bancorp

$18.40

-0.05 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

HCC

Warrior Met Coal

$24.04

0.51 (2.17%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Downgrade
Warrior Met Coal rating change  »

Warrior Met Coal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

, UNH

UnitedHealth

$203.89

10.69 (5.53%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Periodicals
Health insurers prepare for enrollment drop amid ACA uncertainty, WSJ says »

As enrollment for 2018…

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

UNH

UnitedHealth

$203.89

10.69 (5.53%)

CNC

Centene

$93.80

2.88 (3.17%)

WCG

WellCare

$174.03

6.11 (3.64%)

CI

Cigna

$187.20

2.21 (1.19%)

ANTM

Anthem

$187.26

3.5 (1.90%)

HNT

Health Net

HUM

Humana

$240.43

3.26 (1.37%)

AET

Aetna

$155.90

4.46 (2.95%)

EHTH

eHealth

$23.79

-0.61 (-2.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 31

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 14

    Dec

IBM

IBM

$146.54

-0.29 (-0.20%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Recommendations
IBM analyst commentary  »

IBM reported 'best…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

NVO

Novo Nordisk

$49.31

-0.01 (-0.02%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Conference/Events
FDA Endocrinologic & Metabolic Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSLA

Tesla

$355.75

5.15 (1.47%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Periodicals
Tesla employees claim dismissals not performance related, CNBC reports »

Tesla is trying to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ATTU

Attunity

$6.90

0.12 (1.77%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Hot Stocks
Attunity's Replicate adopted by large health insurance provider »

Attunity announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

MYGN

Myriad Genetics

$35.84

-0.26 (-0.72%)

07:10
10/18/17
10/18
07:10
10/18/17
07:10
Hot Stocks
Myriad Genetics BRACAnalysis CDx sPMA by FDA for review »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

MAIN

Main Street

$40.07

-0.1 (-0.25%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Main Street announces semi-annual supplemental cash dividend of 27.5c per share »

Main Street Capital is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

JNJ

Johnson & Johnson

$140.79

4.67 (3.43%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Recommendations
Johnson & Johnson analyst commentary  »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

IONS

Ionis Pharmaceuticals

$63.85

2.7 (4.42%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Ionis collaborates with Seventh Sense Biosystems in blood collection device »

Ionis Pharmaceuticals has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 26

    Oct

LRCX

Lam Research

$194.55

2.19 (1.14%)

07:08
10/18/17
10/18
07:08
10/18/17
07:08
Recommendations
Lam Research analyst commentary  »

Lam Research price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMRN

Immuron

$5.03

0.1 (2.03%)

07:06
10/18/17
10/18
07:06
10/18/17
07:06
Initiation
Immuron initiated  »

Immuron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

, RHHBY

Roche

$31.45

0.27 (0.87%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
BioLineRx: Genentech initiates Phase 1b/2 trial for BL-8040 »

BioLineRx (BLRX)…

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

RHHBY

Roche

$31.45

0.27 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

CEVA

CEVA

$45.40

0.1 (0.22%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
CEVA and Brodmann17 partner for deep learning in edge devices »

CEVA and Broadmann17, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.